A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation Study of NPT088 in Patients With Probable Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 08 Sep 2017
At a glance
- Drugs NPT 088 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Proclara Biosciences
- 05 Sep 2017 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.
- 05 Sep 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Jul 2018.
- 17 Jul 2017 According to a Proclara Biosciences media release, company expects to release topline efficacy data in the summer of 2018.